■HLB PEPT has announced that it signed an exclusive supply agreement for peptide materials with the Indian corporation Biosub on the 5th. Biosub will import the peptide raw materials manufactured by HLB PEPT for research purposes in India. Biosub conducts DNA synthesis and gene analysis and serves universities, research institutions, and biotech corporations in India.
■HUGEL has introduced the 'Hyper PDRN Repair Ampoule' at Wellaj on the 5th. The company combines PDRN (polydeoxyribonucleotide) with a proprietary technology-developed hydrogel in 100% high purity. According to the company, a human application test showed that skin elasticity improved after two weeks of use.
■GeoYoung has announced that it will enhance its pharmaceutical logistics response to heat waves and rainy seasons on the 5th. It operates dehumidifiers, air conditioning units, and constant temperature facilities to securely store pharmaceuticals in a hot and humid environment. To ensure that the quality does not change during the delivery process, it is utilizing cold chain vehicles.
■Daewoong Pharmaceutical has announced that it has signed an academic exchange agreement with the Korean Academy of Comprehensive Health Management on the 5th. The academy includes various screening institutions such as Seoul National University Hospital Gangnam Center, Asan Medical Center, and the Korean Health Management Association. Both sides will collaborate on academic research, advisory services for digital healthcare diagnostic devices and pilot projects, medical volunteer work, and ESG (environmental, social, and governance) activities.
■UBcare has announced that its 'UBPACS-Z' will enter Vietnam on the 5th. UBcare is a digital healthcare company. UBPACS-Z is an imaging information system used in over 4,000 medical institutions nationwide. The company stated, "We will provide services optimized for the local medical environment."
■The National Health Insurance Service Ilsan Hospital has announced that it received a grade of one in the '2024 Drug Benefit Appropriateness Evaluation' on the 5th. The drug benefit appropriateness evaluation has been conducted by the Health Insurance Review & Assessment Service (HIRA) since 2001 to reduce the misuse of antibiotics and injectables and improve the appropriateness of drug prescriptions.
■The National Cancer Center has announced that it has been redesignated as a World Health Organization (WHO) cancer management and prevention collaboration center on the 5th. The designation period lasts four years, until July 2029. The National Cancer Center has been a WHO collaboration center since 2005 for 20 years and is involved in activities for cancer management in the Western Pacific region.